We are pleased to announce that Dr. Zanos recently delivered an impactful presentation on innovative approaches to treating opioid addiction. The lecture highlighted cutting-edge research developments and provided insights into the PROUD study, a pioneering clinical trial investigating ketamine’s potential in preventing opioid relapse.

During this enlightening session, Dr. Zanos shared important findings about the complex relationship between opioid addiction and affective disorders, emphasizing the critical need for more effective therapeutic interventions. Attendees learned about the limitations of current opioid substitution treatments and the promising potential of novel pharmacotherapies.

A significant portion of the presentation focused on the PROUD study – the first drug-interventional clinical trial of its kind in Cyprus. Dr. Zanos discussed how this groundbreaking research explores ketamine’s efficacy in preventing relapse among individuals with opioid use disorder, particularly during extended abstinence periods. The presentation provided valuable insights into the study’s innovative approach to identifying biomarkers that may predict relapse vulnerability and treatment efficacy.

This public engagement event reflects our ongoing commitment to advancing addiction treatment through rigorous scientific research while ensuring effective dissemination of our findings to both the scientific community and the general public.